Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1756 results
August 2023
-
Media ReleaseNovartis completes acquisition of Chinook TherapeuticsAcquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin…
-
Key ReleaseNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaAd hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across…
-
StatementEuropean Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
July 2023
-
Media ReleaseSandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumabIf approved, will be first-of-a-kind biosimilar natalizumab in Europe, for use in all indications of reference biologicPositive CHMP opinion based on evidence from extensive analytical…
-
Media ReleaseSandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipelinePlanned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug…
-
Featured NewsNovartis Financial Results – Q2 2023Novartis announced the company’s financial results for the second quarter and first half of 2023.
-
Key ReleaseNovartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
-
Key ReleaseNovartis réalise une forte croissance de son chiffre d’affaires et de sa marge, relève ses prévisions et annonce un rachat d’actions d’USD 15 milliards¹; le Conseil d’administration approuve le spin-off de Sandoz²Annonce événementielle au sens de l’art. 53 LRAu T2, hausse du chiffre d’affaires de +9% (tcc3, +7% USD) et du résultat opérationnel core de +17% (tcc, +9% USD)Innovative Medicines (IM): hausse du…
-
Key ReleaseNovartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²Ad-hoc-Mitteilung gemäss Art. 53 KRDer Umsatz wuchs im zweiten Quartal um +9% (kWk3, +7% USD), und das operative Kernergebnis verbesserte sich um +17% (kWk, +9% USD)Innovative Medicines (IM)…
-
Media ReleaseNovartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx PharmaDTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary fatty acid ligand-conjugated…
-
Key ReleaseNovartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlookAd hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal…
-
Media ReleaseSandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology spaceHyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars…